Idecabtagene Vicleucel

Definition

A preparation of autologous peripheral blood T-lymphocytes (PBTLs) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA), with potential immunostimulating and antineoplastic activities. Upon administration, idecabtagene vicleucel specifically recognizes and kills BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.

Also known as Abecma, Anti-BCMA CAR T Cells BB2121, Anti-BCMA-CAR-transduced T Cells BB2121, BB2121, BCMA-specific CAR-expressing T Lymphocytes BB2121, Ide-cel, IDECABTAGENE VICLEUCEL — per NCIT

Also identified as

• ATC L01XL07 per RXNORM
• NCIT NCIT:C117729 per NCIT
• SCTID 1156047000 per RXNORM
• SCTID 1156050002 per RXNORM
• UNII 8PX1X7UG4D per RXNORM

Indications

Organ Effects

1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.